Open until 1:00pm : 01582 842096
FREE DELIVERY on most orders over £29
VioVet Insurance

Semintra Oral Solution for Cats

  • 4mg/ml » 30ml Bottle £23.64

Description

Semintra is a new drug developed to help cats which have reduced kidney function. It is very common for the kidneys in cats to deteriorate with age. (Our pet cats probably live much longer than cats in the wild would have done.) Hence a very large proportion of older cats (more than one third) do have less than perfect kidneys and could benefit from taking Semintra. It comes in liquid form and is palatable even to fussy cats, with 90% of cats eating it readily when tests have been conducted. Semintra has been shown to reduce the leakage of proteins in the urine, which helps maintain body weight and muscle mass in affected cats.

Presentation

Clear, colourless to yellowish viscous oral solution. 1 ml contains 4 mg of telmisartan and 0.1 mg Benzalkonium chloride as excipient.

Uses

Reduction of proteinuria associated with chronic kidney disease (CKD) in cats.

Dosage and administration

Oral use.

The recommended dose is 1 mg telmisartan/kg body weight (0.25 ml/kg body weight). The product is to be administered once daily directly into the mouth or with a small amount of food.

Semintra is an oral solution and is well accepted by most cats.

The solution should be given using the measuring syringe provided in the package. The syringe fits onto the bottle and has a kg-body weight scale.

After administration close bottle tightly with cap. To avoid contamination, use the provided syringe only to administer Semintra.

Contra-indications, warnings, etc

Do not use during pregnancy or lactation. The safety of Semintra has not been established in breeding, pregnant or lactating cats.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Special precautions for use in animals

The safety and efficacy of telmisartan has not been tested in cats under the age of 6 months. It is good clinical practice to monitor the blood pressure of cats receiving Semintra which are under anaesthesia.

Due to the mode of action of the veterinary medicinal product, transient hypotension may occur. Symptomatic treatment, e.g. fluid therapy, should be provided in case of any clinical signs of hypotension.

As known from substances acting on the Renin-Angiotensin-Aldosterone System (RAAS), a slight decrease in red blood cell count may occur. Red blood cell count should be monitored during therapy.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Avoid eye contact. In case of accidental eye contact, rinse eyes with water. Wash hands after use.

Pregnant women should take special care to avoid contact with the product because substances acting on the RAAS, such as Angiotensin Receptor Blockers (ARBs) and ACE inhibitors (ACEi), have been found to affect the unborn child during pregnancy in humans.

People with hypersensitivity to telmisartan or other sartans/ARBs should avoid contact with the veterinary medicinal product.

The following mild and transient gastrointestinal signs have rarely been observed in a clinical study (in order of decreasing frequency): mild and intermittent regurgitation, vomiting, diarrhoea or soft faeces.

Elevated liver enzymes have been very rarely observed and values normalised within a few days following cessation of therapy.

Effects attributable to the pharmacological activity of the product observed at the recommended treatment dose included reductions in blood pressure and decreases in red blood cell counts.

During concomitant therapy with amlodipine at the recommended dose no clinical evidence of hypotension was observed.

After administration of up to 5-fold of the recommended dose for 6 months, no adverse reactions were observed other than those mentioned above.

Administration of the product at overdose (up to 5-fold of the recommended dose for 6 months) resulted in marked reductions in blood pressure, decreases in red blood cell count (effects attributable to the pharmacological activity of the product) and increases in Blood Urea Nitrogen (BUN). These effects are unlikely to be observed under clinical conditions. However, in the event that transient hypotension does occur, symptomatic treatment, e.g. fluid therapy, should be provided.

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary products.

Pharmaceutical precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Legal category

POM-V

Packaging Quantities

Cardboard box containing one 45 ml HDPE bottle filled with 30 ml closed with a LDPE plug-in adapter and a tamper-proof child resistant closure and a measuring syringe.

Further information

Pharmacodynamic properties

Telmisartan is an orally active and specific angiotensin II receptor (type AT1) antagonist which causes a dose dependent decrease in mean arterial blood pressure in mammalian species including the cat. In a clinical trial in cats with chronic kidney disease, a reduction in proteinuria was seen within the first 7 days after the start of treatment.

Telmisartan displaces angiotensin II from its binding site at the AT1 receptor subtype. Telmisartan selectively binds to the AT1 receptor and does not show affinity for other receptors, including AT2 or other less characterised AT receptors. Stimulation of the AT1 receptor is responsible for pathologic effects of angiotensin II in the kidney and other organs associated with angiotensin II such as vasoconstriction, retention of sodium and water, increased aldosterone synthesis and organ remodeling. Effects associated with stimulation of the AT2 receptor such as vasodilatation, natriuresis and inhibition of inappropriate cell growth are not suppressed. The receptor binding is long lasting due to the slow dissociation of telmisartan from the AT1 receptor binding site. Telmisartan does not exhibit any partial agonist activity at the type AT1 receptor.

Hypokalemia is associated with CKD, however telmisartan does not affect potassium excretion, as shown in the clinical field trial in cats.

Pharmacokinetic properties

Absorption Following oral administration of 1 mg/kg body weight telmisartan to cats , plasma-concentration-time curves of the parent compound are characterised by rapid absorption, with maximum plasma concentrations (Cmax) achieved after 0.5 hours (tmax). For both, Cmax-values, and AUC-values, a dose proportional increase over the dose range from 0.5 mg/kg to 3 mg/kg was observed. As determined by AUC, food consumption does not affect the overall extent of absorption of telmisartan. Telmisartan is highly lipophilic and has rapid membrane permeability kinetics, which facilitates easy distribution into tissue. No significant gender effect was seen. No clinically relevant accumulation was observed following multiple dose administration once daily for 21 days. The absolute bioavailability after oral administration was found to be 33 %.

Distribution In vitro studies in human, dog, mouse and rat plasma showed a high plasma protein binding (> 99.5 %), mainly to albumin and α-1-acid glycoprotein.

Metabolism Telmisartan is metabolised by conjugation to the glucuronide of the parent compound. No pharmacological activity has been shown for the conjugate. From in vitro and ex vivo studies with feline liver microsomes it can be concluded that telmisartan is effectively glucuronidated in the cat. The glucuronidation resulted in the formation of the 1-O-acylglucuronide metabolite of telmisartan.

Elimination The terminal elimination half life (t 1/2) ranged from 7.3 hours to 8.6 hours, with mean value 7.7 hours. After oral administration, telmisartan is almost exclusively excreted with faeces mainly as unchanged compound.

Marketing Authorisation Holder (if different from distributor)

Boehringer Ingelheim Vetmedica GmbH

55216 Ingelheim/Rhein

Germany

Marketing authorisation number

EU/2/12/146/001.

GTIN (Global Trade Item No)

Semintra 4 mg/ml oral solution for cats

5012917030167

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Freephone*: 0800 084 2608
  • Mon - Fri: 8:30am - 6:00pm
  • Sat: 9:00am - 1:00pm
  • Email: support@viovet.co.uk

All prices include VAT where applicable. *The freephone number is free from most UK landlines only, mobiles are usually charged so we'd recommend calling our landline from your mobile or internationally.

Reviews of Semintra Oral Solution for Cats

Read our customers' reviews of Semintra Oral Solution for Cats

Questions & Answers for Semintra Oral Solution for Cats

Below are some recent questions we've received regarding Semintra Oral Solution for Cats, including answers from our team.

Ask Your Own Question

Does Semintrea slow progression of CKD

12th Nov 2016
David
  • VioVet Customer Since: November 2016
  • From: Surrey, United Kingdom

Is the effect of Semintrea just to reduce urine protien? Does it slow progression of the CKD? Our 16 year old cat has a urine protein of 0.10 g/l and a urine prot/creatinine ratio of 0.25 which the test results classify as borderline-proteinuric. Would semintrea benefit her? She also has hyperthyroidism (79 nmol/l thyroxin) which is being treated with Vidalta (just started). She has no outward symptoms apart from some weight loss.

  • Veterinary Surgeon

The active substance in Semintra, telmisartan, is an ‘angiotensin II receptor antagonist’, which means that it blocks the action of a hormone in the body called angiotensin II. Angiotensin II is a powerful vasoconstrictor (a substance that constricts blood vessels). By blocking the receptor to which angiotensin II normally attaches, telmisartan stops the hormone having an effect, allowing the blood vessels to expand. This allows blood pressure to drop with a resulting decrease in protein in the urine which may slow down progression of kidney disease. If your cat is losing weight then Semintra may well help. Of course hyperthyroidism causes weight loss too but if your cat is losing any protein in her urine then this will contribute. It would be up to your vet to advise how beneficial Semintra would be to your cat at this stage.

Dosage????

16th Sep 2016
Chrissy Anderson
  • VioVet Customer Since: September 2016
  • From: Greater Manchester, United Kingdom

My cat was recently prescribed this with a vague excuse why...and I was told to give him 4kg a day but when I got hone I found that the syringe was in mg/ml? when i rang to query this the vets did not seem to understan what I was asking? can you help


thanks

  • Veterinary Surgeon

I can see your confusion. The syringe is telling you that there are 4mg of semintra in 1ml of solution. This is not something you need to worry about though. To simplify things the scale on the syringe from 1-8 represents a kg-bodyweight scale. If your cat weighs 4kg you need to fill the syringe up to 4 on the scale.

Administering Semintra while pregnant

21st Jun 2016
Belle

Hello. My 12 year old tabby has sadly been diagnosed with early stage CKD and proteinuria. She also has blood in her urine which is being attributed to idiopathic cystitis as an ultrasound revealed nothing suspicious. She has been prescribed Semintra which I've been giving her for a month every morning.
I've just discovered I'm in the early stages of pregnancy and I see on the leaflet that Semintra should be handled with caution/not at all in pregnancy. If my partner gives her the medication is this adequate precaution? Should I stay away from her completely which I would hate and would be very hard to do when I live with her? Can I still stroke her or is that dangerous to me?
I asked my vet nurse, Dr and pharmacist and due to the new nature of the drug they were not able to offer much advice apart from to get my partner to medicate the cat and stay away from her for an hour afterwards. Please could you advise as I would like a vet's take on it?
Many thanks

John Cousins
  • Veterinary Surgeon

I am sure that close contact with your cat will be completely safe as far as this medication is concerned. There is a theoretical risk if you have a litter tray and you handle that, because the compound is excreted unchanged in the faeces. However I am sure that normal hygiene measures will be fully adequate to protect you there. (A much more real danger to you from a litter tray would be Toxoplasmosis, so please ask your doctor about this if you are not aware of it.) I suppose if she had some residual medication in her mouth and then bit you, there would be a slight risk, but you can assess how likely that really is. Again if she has some in her mouth then grooms herself, some will be present on her coat. However we are getting into the realms of theoretical tiny risks here and there are many greater dangers out there than this. The amount that you could actually ingest through stroking her is ridiculously small and quite insignificant. The danger to pregnant women comes really from being prescribed the medication themselves, so the dose would be immensely higher. Basically as long as you do not have any direct contact with the medication, all will be well. Perhaps wash your hands before eating etc while pregnant, for lots of reasons. Otherwise I do not think this should be a concern of yours now.

I hope your pregnancy goes well in every way and that you enjoy motherhood in all its complexities!

WILL SEMINTRA SOLUTION REPLACE FORTEKOR AND AMLODIPINE?

25th Nov 2015
JO

MY CAT IS 16 AND HAS KIDNEY PROBLEMS, HE IS ON IPAKITINE POWDER, AMLODIPINE, FORTEKOR AND METACAM. THE VET HAS TOLD ME THAT I CAN REPLACE AMLODIPINE AND FORTEKOR WITH SEMINTRA SOLUTION. IS THIS THE CASE AS THE AMLODIPINE IS FOR HIGH BLOOD PRESSURE?

John Cousins
  • Veterinary Surgeon

I would certainly think that Semintra could replace the Fortekor. It might well reduce blood pressure too in time, but by a different mechanism than amlodipine.You could perhaps maintain the amlodipine initially and measure blood pressure periodically while then withdrawing the it. You could certainly find that amlodipine is not needed, depending perhaps on how high the blood pressure has been before. Your vet is best able to advise on this.

Will it hrlp my poor puss prudence aged 20?

25th Jan 2014
sue fisher

Prudence is 20,has ckd hyperthroidism and bp of. 150 .she had just had her medication changed from fortecor to semintra, and akso takes istin and felimazole.
Her illness has occurred in tge last 6 months and sge has deteriorated, lost weight and is quire frail,.
I woukd do anything to make her bettet.
Please can you give me some advice.
Thank you
sue

John Cousins
  • Veterinary Surgeon

Prudence is so old, you must be very proud of her. Semintra is designed for cats just like her and it should help, but nothing will make her young again. It can help to reduce the weight loss by reducing the amount of protein which leaks out in the urine. We would recommend you continue with it.